Magnetic Resonance Spectroscopy in Myocardial Disease
Overview
Radiology
Authors
Affiliations
Magnetic resonance spectroscopy (MRS) is the only noninvasive, nonradiation exposure technique for the investigation of cardiac metabolism in vivo. MRS uses magnetic resonance signals from nuclei, such as (31)phosphorus, (1)hydrogen, and (23)sodium, to provide comprehensive metabolic and biochemical information about cardiac muscle. This method is highly versatile and can provide metabolic insights into the role of cardiac metabolism, in particular, cardiac energetics, in a wide number of conditions, including hypertensive, valvular, and ischemic heart disease, heart failure, and cardiac transplantation, as well as cardiomyopathies. This method can also be used to monitor patient responses to therapeutic interventions: pharmacologic, surgical, or interventional. When combined with cardiovascular magnetic resonance imaging, MRS enables detailed pathophysiologic insights into the inter-relations among cardiac structure, function, perfusion, and metabolism. However, MRS is currently used primarily as a research tool because of low temporal and spatial resolution and low reproducibility. It is hoped that future technical developments and use of higher magnetic field strengths (such as 7-T) may enable application of cardiac MRS in clinical practice.
Ungated, plug-and-play preclinical cardiac CEST-MRI using radial FLASH with segmented saturation.
Weigand-Whittier J, Wendland M, Lam B, Velasquez M, Vandsburger M Magn Reson Med. 2024; 93(4):1793-1806.
PMID: 39607872 PMC: 11785487. DOI: 10.1002/mrm.30382.
Korosoglou G, Sagris M, Florian Andre , Steen H, Montenbruck M, Frey N Sci Rep. 2024; 14(1):1094.
PMID: 38212323 PMC: 10784294. DOI: 10.1038/s41598-023-50835-5.
Magnetic resonance imaging of cardiac metabolism in heart failure: how far have we come?.
Yurista S, Eder R, Kwon D, Farrar C, Yen Y, Tang W Eur Heart J Cardiovasc Imaging. 2022; 23(10):1277-1289.
PMID: 35788836 PMC: 10202438. DOI: 10.1093/ehjci/jeac121.
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial.
Lewis G, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert E Nat Med. 2021; 27(8):1477-1482.
PMID: 34385704 DOI: 10.1038/s41591-021-01452-0.
YaQoub L, Elgendy I, Pepine C Am J Med. 2021; 134(11):1321-1329.
PMID: 34343507 PMC: 8754003. DOI: 10.1016/j.amjmed.2021.06.038.